Corvus Pharmaceuticals Inc

Healthcare · Biotechnology

10.70$ -1.5% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

Corvus Pharmaceuticals Inc (CRVS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 239 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet CRVS
Line item	Q3 16	Q4 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	150	140	127	115	105	95	149	138	127	118	112	103	92	84	74	64	56	86	109	109	119	109	101	93	80	68	58	58	52	46	40	65	59	69	59	89	80	71	253	239
Current Assets	146	135	123	112	101	90	145	134	125	115	107	98	86	79	70	61	53	45	69	69	79	71	64	59	51	44	36	38	33	28	23	48	43	54	45	76	67	58	240	221
Cash	5.6	135	10	34	44	90	103	28	41	115	39	30	9.1	5.2	23	21	23	16	45	59	72	63	31	28	25	13	9.7	7.7	20	13	7.5	15	4.7	8.7	5.0	15	2.9	4.6	40	19
Cash & Short-Term Investments	145	135	122	110	100	90	144	133	123	115	106	97	86	78	69	59	51	44	68	66	76	69	63	57	50	42	34	37	32	27	22	47	42	52	44	74	66	57	237	215
Receivables	0.3	0.4	0.1	0.1	0.1	0.1	0.2	0.3	0.3	0.3	0.4	0.3	0.3	0.3	0.2	0.1	0.1	0.1	0.1	0.0	0.3	0.5	0.4	0.4	0.5	0.6	0.5	0.0	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.3	0.3	0.4	1.2	1.8
Inventory	0.2	-1.1	0.2	0.2	0.4	-0.9	0.5	0.4	0.2	-0.6	0.5	0.6	-0.9	-0.8	0.5	0.8	0.6	-0.5	0.5	2.5	2.0	0.0	0.8	1.3	0.7	-0.7	-0.6	0.7	0.7	–	23	–	–	–	–	–	–	–	–	–
Property, Plant & Equipment	2.9	3.2	3.1	3.0	2.9	2.7	2.5	2.3	2.2	2.2	4.8	4.5	4.1	3.8	3.4	3.1	1.0	2.6	0.8	1.9	3.4	3.6	3.3	3.2	2.9	2.6	0.3	0.3	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	6.9	7.3	8.9	11	11	9.9	11	11	8.4	7.9	12	13	12	13	14	13	14	13	15	13	14	12	12	12	16	12	9.3	8.6	7.7	6.9	6.7	13	46	36	10	9.2	8.7	9.9	13	14
Current Liabilities	5.6	7.3	7.6	9.5	10.0	9.9	11	9.8	7.7	7.9	8.6	11	8.7	10	12	12	12	12	14	12	11	9.7	9.3	10	14	11	8.3	7.9	7.3	6.9	6.7	13	46	35	9.3	8.5	8.1	9.4	12	14
Short-Term Debt	–	–	–	–	–	–	–	–	–	–	0.8	0.8	0.8	0.9	0.9	1.0	1.0	1.1	1.1	1.2	1.0	1.0	1.1	1.1	1.2	1.2	1.3	1.3	1.3	1.4	1.0	0.7	0.4	0.2	0.3	0.4	0.4	0.4	0.4	0.5
Accounts Payable	2.4	1.9	2.4	4.1	3.6	3.5	3.5	2.3	1.9	2.0	2.3	2.6	1.9	2.4	3.4	2.8	2.6	3.5	4.9	2.9	2.3	1.6	2.2	2.7	4.2	2.0	1.4	2.1	1.4	1.5	1.6	1.2	1.9	2.6	1.3	3.1	2.0	2.5	4.7	4.0
Long-Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	–	3.0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Shareholders' Equity	143	133	118	105	94	85	137	127	119	110	101	90	80	71	60	51	42	72	94	96	105	97	90	80	65	56	49	49	44	39	33	51	12	33	49	80	72	61	241	225
Retained Earnings	-57	-68	-84	-99	-112	-124	-138	-149	-160	-170	-182	-195	-206	-217	-230	-241	-250	-223	-235	-246	-257	-266	-275	-283	-298	-308	-316	-322	-328	-335	-340	-345	-385	-397	-382	-390	-400	-412	-426	-444
Shares Outstanding	20	20	20	20	21	21	23	29	29	29	29	29	29	29	29	29	30	30	35	42	44	47	47	47	47	47	47	47	49	49	49	60	67	68	75	78	83	80	90	92

Showing the most recent 40 periods — older statements are on file for this stock.

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings